title: Agitated delirium associated with therapeutic doses of sustained-release bupropion.
abstract: METHODS
  We report a case of a patient initiated on therapeutic doses of sustained-release bupropion for the management of major depressive disorder who subsequently developed acute agitated delirium that required ICU level care. This patient's history was significant for alcohol and cannabis abuse but he was currently detoxified and beyond the withdrawal period. Throughout the course of treatment, all maintenance medications, including bupropion, were discontinued and the patient required escalating doses of benzodiazepines and typical antipsychotics to resolve symptoms. The patient's delirium subsided after approximately 5 days.
  
  
  CONCLUSIONS
  Dopamine is thought to play a role in the pathophysiology of delirium and given the mechanism of action of this drug and the presence of delirium risk factors in our patient, we are faced with a likely causative factor of this acute delirious episode.
authors: Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, 410 N 12th St, PO Box 980533, Richmond, VA 23298-0533, USA. dmack2@vcu.edu
authors: Diana R
authors: DR
authors: Mack
authors: Liza
authors: L
authors: Barbarello-Andrews
authors: Mei T
authors: MT
authors: Liu
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016642:Bupropion / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003422:Critical Care; D003692:Delayed-Action Preparations; D003693:Delirium / Q000139:chemically induced*; D003865:Major Depressive Disorder / Q000188:drug therapy; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011595:Psychomotor Agitation; D012307:Risk Factors
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D018765:Dopamine Uptake Inhibitors; D016642:Bupropion